Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockBearish
6
Neutral
3
Bullish
5
Bearish
6
Neutral
3
Bullish
37
Bearish
0
Neutral
0
Bullish
32
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
J.B. Chemicals & Pharmaceuticals Limited is a leading pharmaceutical company established in 1976, heavily engaged in the manufacture and marketing of diverse pharmaceutical formulations, herbal remedies, and APIs.
The company continues to be one of the fastest growing organizations in the Indian pharmaceutical market, demonstrating superior performance with notable growth in key brands such as Cilacar, Sporlac, and Razel.
J.B. Chemicals recently expanded through strategic acquisitions, including the Azmarda brand from Novartis, which fortifies its presence in the cardiology market.
The company places a strong focus on expanding its domestic and international presence with a robust order book, driving both revenue and profit growth significantly above the industry average.
Pharmaceuticals & Biotechnology
Pharmaceuticals
34,551 Cr
Low Risk
45.8
34.2
1.7
9.1
2,195.00
1,510.05
Sales CAGR
Profit CAGR
ROE
ROCE
Upcoming Result Date: May 10, 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) is currently trading at 2,155.75 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
J.B. Chemicals & Pharmaceuticals Limited is a leading pharmaceutical company established in 1976, heavily engaged in the manufacture and marketing of diverse pharmaceutical formulations, herbal remedies, and APIs. The company continues to be one of the fastest growing organizations in the Indian pharmaceutical market, demonstrating superior performance with notable growth in key brands such as Cilacar, Sporlac, and Razel. J.B. Chemicals recently expanded through strategic acquisitions, including the Azmarda brand from Novartis, which fortifies its presence in the cardiology market. The company places a strong focus on expanding its domestic and international presence with a robust order book, driving both revenue and profit growth significantly above the industry average.
Over the past 52 weeks, J B Chemicals & Pharmaceuticals Ltd has traded between a low of ₹1,510.05 and a high of ₹2,195.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
J B Chemicals & Pharmaceuticals Ltd has a market capitalization of approximately 34,550.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
J B Chemicals & Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 45.84 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 34,550.63 Cr, J B Chemicals & Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
J B Chemicals & Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of J B Chemicals & Pharmaceuticals Ltd is 45.84. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
NCLT Ahmedabad directed both companies to convene meetings of equity shareholders for the proposed amalgamation under Sections 230-232 of the Companies Act, 2013, with a quorum of 30 shareholders.
It directed both companies to convene equity shareholder meetings for the amalgamation under Sections 230-232, to be held within 45 days via VC/OVAM, with specified meeting oversight appointments.
A corrigendum order is a legal document issued by a tribunal, in this case the NCLT, to correct errors or provide clarifications in a previous order. It's a procedural step to ensure the accuracy of the legal documentation for the merger.
The 'Biopharma Shakti' initiative, with a ₹10,000 crore outlay, is the most significant announcement. It aims to make India a global hub for biologics and biosimilars, presenting a major long-term growth opportunity for pharma companies.
Earnings Conference Call
J B Chemicals & Pharmaceuticals will host an investor/analyst conference call on May 12, 2026 at 8:30 AM IST to discuss Q4 FY26 results (financials to be announced May 11); dial-in and registration details provided.
Results Approval Meeting
Company will hold a board meeting on May 11, 2026 to approve standalone and consolidated audited financial results for the quarter and year ended March 31, 2026 and consider recommending a final dividend.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2482.00 | 42,092 Cr | 41.23 | 24.65 | 2.17 | 55.94 | 74.64 | 27.86 | ||
1439.00 | 39,369 Cr | 43.27 | 5.30 | 0.26 | 13.33 | 17.89 | 7.73 | ||
2895.85 | 37,883 Cr | 35.87 | 8.37 | 0.00 | 23.33 | 29.09 | 17.16 | ||
2145.90 | 34,551 Cr | 45.84 | 9.08 | 0.70 | 18.88 | 25.16 | 16.00 | ||
1750.35 | 31,377 Cr | 37.04 | 3.28 | 0.95 | 8.27 | 12.46 | 7.18 | ||
1679.95 | 31,123 Cr | 33.67 | 6.29 | 0.00 | 18.67 | 21.76 | 9.79 | ||
1348.20 | 26,111 Cr | 122.59 | 5.29 | 0.00 | 5.75 | 7.39 | 2.31 | ||
| Median: 7 Co. | — | 1750.35 | 34,551 Cr | 41.23 | 6.29 | 0.26 | 18.67 | 21.76 | 9.79 |
